| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
(E/Z)-BCI primarily targets dual-specificity phosphatase 6 (DUSP6) and DUSP1, which are mitogen-activated protein kinase phosphatases involved in the regulation of MAPK signaling pathways. It has EC50 values of 13.3 μM for DUSP6 and 8.0 μM for DUSP1 in cells. By inhibiting DUSP1/6, the compound modulates inflammatory responses. It also activates Nrf2 signaling and inhibits the NF-κB pathway. (E)-BCI induces apoptosis via ROS generation and activation of the intrinsic mitochondrial pathway.
|
|---|---|
| ln Vitro |
In a time- and dose-dependent way, (E/Z)-BCI hydrochloride (2-10 μM; 72 hours) dramatically lowers the cell viability of gastric epithelial cells GES1, GC cell lines, and AGS cell lines [2]. In LPS-activated macrophages, (E/Z)-BCI hydrochloride (0.5–4 μM; 24 hours) dramatically reduces DUSP6 expression [1]. The expression of IL-1β, TNF-α, and IL-6 mRNA in LPS-activated macrophages was considerably reduced by (E/Z)-BCI hydrochloride (0.5-2 μM; 24 hours) treatment [1]. When LPS-activated macrophages are exposed to (E/Z)-BCI hydrochloride, they produce less ROS and activate the Nrf2 pathway [1]. The gastric cancer (GC) cells are more resistant to invasion, migration, and proliferation when exposed to (E/Z)-BCI hydrochloride, which also increases the cytotoxicity of CDDP (increased CDDP-induced cell death and apoptosis) [2].
In vitro, (E/Z)-BCI functions as a DUSP1/DUSP6 inhibitor with EC50 values of 13.3 μM and 8.0 μM in cells, respectively. It attenuates LPS-induced macrophage inflammation and ROS generation through activation of Nrf2 signaling and inhibition of the NF-κB pathway. (E)-BCI induces apoptosis via generation of reactive oxygen species (ROS) and activation of the intrinsic mitochondrial pathway in H1299 lung cancer cells. Its activity is typically evaluated in macrophage and cancer cell models. |
| ln Vivo |
Treatment with (E/Z)-BCI hydrochloride (35 mg/kg; intraperitoneal injection; every 7 days; for 4 weeks; female BALB/c nude mice) increased the effectiveness of cisplatin in the PDX model [2].
In vivo, (E/Z)-BCI has been studied for its anti-inflammatory effects in models of chronic inflammatory diseases such as rheumatoid arthritis, atherosclerosis, and cancer. As a DUSP6 inhibitor and modulator of Nrf2 and NF-κB pathways, it has potential therapeutic applications in inflammatory diseases. However, specific in vivo efficacy data, including dosing regimens and animal models, are not extensively detailed in the available literature. Further studies are needed to fully characterize its in vivo pharmacological profile. |
| Enzyme Assay |
Cell-free assays for (E/Z)-BCI involve evaluating its inhibitory activity against DUSP1 and DUSP6. Enzyme activity is monitored using fluorogenic substrates that are dephosphorylated by active DUSPs. Inhibition is assessed by incubating DUSP1 or DUSP6 with varying concentrations of (E/Z)-BCI and measuring residual activity. EC50 values (13.3 μM for DUSP6, 8.0 μM for DUSP1) are determined from dose-response curves. Chemical purity and identity are confirmed by HPLC and NMR analysis. The compound is typically dissolved in DMSO for assay preparation.
|
| Cell Assay |
Cell viability assay [2]
Cell Types: gastric epithelial cells GES1, GC cell lines (HGC27, SGC7901, MKN45, BGC823, MGC803, SNU216, NUGC4), AGS cell lines. Tested Concentrations: 2 μM, 4 μM, 6 μM, 8 μM, 10 μM Incubation Duration: 72 hrs (hours) Experimental Results: Cell viability was Dramatically diminished in a time- and dose-dependent manner. Western Blot Analysis[1] Cell Types: RAW264.7 macrophages (LPS-activated macrophages) Tested Concentrations: 0.5 μM, 1 μM, 2 μM, 4 μM Incubation Duration: 24 hrs (hours) Experimental Results: DUSP6 protein activated by LPS Dramatically down-regulated macrophages. RT-PCR[1] Cell Types: RAW264.7 macrophages (LPS-activated macrophages) Tested Concentrations: 0.5 μM, 1 μM, 2 μM Incubation Duration: 24 hrs (hours) Experimental Results: IL-1β, TNF-α, and IL Expression of -6 mRNA was Dramatically inhibited in LPS-activated macrophages. In vitro cellular assays for (E/Z)-BCI typically involve treating macrophages (e.g., RAW 264.7) with LPS to induce inflammation. Cells are pre-treated with various concentrations of (E/Z)-BCI. ROS generation is measured using fluorescent probes such as DCFH-DA. Inflammatory cytokine production is measured by ELISA. Nrf2 activation and NF-κB inhibition are assessed by western blotting. In H1299 lung cancer cells, apoptosis is evaluated using Annexin V/PI staining and caspase activity assays. Dose-response curves are generated to determine EC50 values. |
| Animal Protocol |
Animal/Disease Models: Patient-derived xenograft (PDX) model (4-5 weeks old female BALB/c nude mice) [2]
Doses: 35 mg/kg Route of Administration: intraperitoneal (ip) injection; once every 7 days; 4-week Experimental Results: Tumor weight in PDX models treated with CDDP was Dramatically suppressed compared to tumors in PDX model mice treated with either drug alone. In vivo animal studies for (E/Z)-BCI are conducted in models of inflammatory diseases and cancer. The compound is administered via various routes including oral gavage or intraperitoneal injection. Inflammatory markers in serum and tissues are measured using ELISA. Tumor growth is monitored in cancer models. However, specific dosing regimens and experimental protocols are not extensively documented in the available literature. Standard protocols for evaluating anti-inflammatory and anticancer agents would typically be employed. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (E/Z)-BCI include a molecular weight of 334.41 g/mol and molecular formula C22H18ClNO (approximate). The compound is soluble in DMSO (63 mg/mL). As a small molecule, it is expected to have moderate oral bioavailability and tissue penetration. Detailed ADME parameters such as half-life, Cmax, and AUC are not extensively reported in the available literature. The compound is typically stored at appropriate conditions as a research reagent.
|
| Toxicity/Toxicokinetics |
The toxicity profile of (E/Z)-BCI has not been extensively characterized in published literature. As a DUSP inhibitor and modulator of inflammatory pathways, potential toxicities may include effects on immune function and normal cell signaling. Standard preclinical safety studies would include acute and sub-chronic toxicity assessments in rodent models. The compound is intended for research use only and not for therapeutic applications in humans. Standard safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
(E/Z)-BCI (NSC 150117) is a DUSP1/DUSP6 inhibitor with EC50 values of 13.3 μM and 8.0 μM in cells. It attenuates LPS-induced macrophage inflammation and ROS generation via Nrf2 activation and NF-κB inhibition. (E)-BCI induces apoptosis via ROS generation in H1299 lung cancer cells. (E/Z)-BCI is a research tool for studying inflammation, cancer, and MAPK signaling.
|
| Molecular Formula |
C22H23NO
|
|---|---|
| Molecular Weight |
317.424125909805
|
| Exact Mass |
317.177
|
| CAS # |
15982-84-0
|
| Related CAS # |
BCI;1245792-51-1;BCI hydrochloride;95130-23-7
|
| PubChem CID |
5475586
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
470
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CCC(CC1)NC\2C3=CC=CC=C3C(=O)/C2=C\C4=CC=CC=C4
|
| InChi Key |
XJDKPLZUXCIMIS-HKWRFOASSA-N
|
| InChi Code |
InChI=1S/C22H23NO/c24-22-19-14-8-7-13-18(19)21(23-17-11-5-2-6-12-17)20(22)15-16-9-3-1-4-10-16/h1,3-4,7-10,13-15,17,21,23H,2,5-6,11-12H2/b20-15-
|
| Chemical Name |
(2Z)-2-benzylidene-3-(cyclohexylamino)-3H-inden-1-one
|
| Synonyms |
(E/Z)BCI; (E/Z) BCI
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1504 mL | 15.7520 mL | 31.5040 mL | |
| 5 mM | 0.6301 mL | 3.1504 mL | 6.3008 mL | |
| 10 mM | 0.3150 mL | 1.5752 mL | 3.1504 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
